[ad_1] Marker jumps 32% on pre-clinical data for T cell therapy [ad_2] Source link
Browsing: preclinical
[ad_1] Klaus Vedfelt PTC Therapeutics (NASDAQ:PTCT) has decided to discontinue its preclinical and early research programs in its gene therapy…
[ad_1] Orchard Therapeutics (Nasdaq: NASDAQ:), a global gene therapy leader, today announced multiple clinical and preclinical updates from its portfolio…
[ad_1] LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) announced that, as recently reported in The Journal of Clinical Investigation, PP2A, the…